Why Acadia Pharmaceuticals Stock Is Crushing It Today [The Motley Fool]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: The Motley Fool
Why Acadia Pharmaceuticals Stock Is Crushing It Today Great Q2 results powered by strong momentum for antipsychotic drug Nuplazid have investors fired up. Shares of Acadia Pharmaceuticals ( NASDAQ:ACAD ) are soaring today, up 17.8% as of 11:27 a.m. EDT, after the drugmaker announced strong second-quarter financial results . The main reason investors are so pumped up about Acadia is due to just how impressive the company's Q2 results were. Acadia reported that its revenue in the second quarter increased 46% year over year to $83.2 million, fueled by continued momentum for antipsychotic drug Nuplazid. This easily topped the consensus Wall Street estimate of a little over $72 million in revenue. While Acadia announced a net loss of $54.9 million, or $0.38 per share, its bottom line in Q2 was much better than the net loss of $63 million, or $0.51 per share, in the prior-year period. It also beat analysts' average estimate of a net loss of $0.45 per share. One quarter of exceeding Wall St
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual MeetingBusiness Wire
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.MarketBeat
- Taysha draws bullish view at Piper Sandler on lead asset [Seeking Alpha]Seeking Alpha
- Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 2/27/24 - Miss
ACAD
Sec Filings
- 4/15/24 - Form 3
- 4/9/24 - Form 4
- 4/9/24 - Form 4
- ACAD's page on the SEC website